Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Presenting at Cowen Healthcare Conference

8 Mar 2018 07:00

RNS Number : 0452H
Realm Therapeutics PLC
08 March 2018
 

Realm Therapeutics to Present at the Cowen and Company 38th Annual Health Care Conference

 

MALVERN, PA, March 8 2018 - Realm Therapeutics plc (AIM:RLM), a clinical stage biopharmaceutical company focused on developing novel therapeutics in immune-mediated diseases, announced today that Alex Martin, CEO, will be presenting at the Cowen and Company 38th Annual Health Care Conference, on Tuesday, March 13, 2018 at 10:00 a.m. ET at the Boston Marriott Copley Place. 

 

A live and archived webcast of the Cowen presentation will be available on the Events and Presentations page of the Company's website. An updated copy of Realm's corporate presentation will be available on March 13 on the Company's website at www.realmtx.com

 

About Realm Therapeutics

 

Realm Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel therapeutics that target the intersection between innate and adaptive immunity, to influence immune signaling and to change the course of immune-mediated diseases in adults and children. Realm's lead drug development programs utilize the Company's proprietary immunomodulatory technology for the treatment of Allergic Conjunctivitis (PR013) and Atopic Dermatitis (PR022) and Realm is exploring its efficacy in Acne and additional Dermatology and Ophthalmology indications as well as other disease areas. For more information on Realm Therapeutics, Inc. please visit www.realmtx.com.

 

Forward Looking Statements

 

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

Contact:

Realm Therapeutics plc

Alex Martin, Chief Executive Officer

Marella Thorell, Chief Financial Officer and Chief Operating Officer

Outside US: +44 (0) 20 3727 1000

US: +1 212 600 1902

 

Argot Partners

Stephanie Marks

+1 212 600 1902

 

FTI Consulting

Simon Conway / Mo Noonan

+44 (0) 20 3727 1000

 

N+1 Singer (Nominated Adviser and Broker) Aubrey Powell / Jen Boorer

+44 (0) 20 7496 3000

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NRAEAPDXELAPEFF
Date   Source Headline
31st Jan 20139:00 amRNSTotal Voting Rights
17th Jan 20135:22 pmRNSHolding(s) in Company
17th Jan 20134:44 pmRNSHolding(s) in Company
17th Jan 20134:42 pmRNSHolding(s) in Company
17th Jan 20134:37 pmRNSHolding(s) in Company
17th Jan 20134:33 pmRNSHolding(s) in Company
17th Jan 20134:25 pmRNSHolding(s) in Company
17th Jan 20134:24 pmRNSHolding(s) in Company
10th Jan 20134:53 pmRNSBoard Changes
10th Jan 20134:36 pmRNSResult of General Meeting
19th Dec 20123:25 pmRNSPublication of Prospectus
19th Dec 20127:00 amRNSRestructuring of Loan Notes and Placing
19th Nov 20127:00 amRNSInterim Management Statement
15th Nov 20127:00 amRNSLohas partnering agreement
9th Oct 20127:00 amRNSPuriCore Signs Two Major US Deals
3rd Oct 20127:00 amRNSPositive Results from ActiVita Research
15th Aug 20122:34 pmRNSBlocklisting Application
13th Aug 20121:07 pmRNSBlocklisting Interim Review
8th Aug 20121:53 pmRNSNotification of Executive Chairman's Option Grant
6th Aug 20127:00 amRNSHalf Yearly Report
26th Jul 20127:00 amRNSNotice of Results
26th Jun 201211:54 amRNSHolding(s) in Company
25th Jun 20129:00 amRNSDirector's Dealing
12th Jun 201211:36 amRNSResult of AGM
30th May 20127:00 amRNSBoard and Organisational Changes
21st May 20127:00 amRNSAnnual Information Update
30th Apr 20127:00 amRNSDirector Dealing and Share Option Grant
26th Apr 20127:00 amRNSInterim Management Statement
26th Apr 20127:00 amRNSFinal Results
25th Apr 20129:13 amRNSNotice of Results
29th Mar 20127:00 amRNSAppointment of New Chairman and Board Changes
13th Feb 20127:00 amRNSNotification of Director's Details
3rd Feb 20123:22 pmRNSDirectors dealings and share option grants
2nd Feb 20124:59 pmRNSBlocklisting Interim Review
1st Feb 20127:02 amRNSBBSRC Industrial Partner Award
1st Feb 20127:01 amRNSDirectorate Change
1st Feb 20127:00 amRNSPre-Close Trading Update
17th Jan 20127:00 amRNSPuriCore Aqualox EPA confirmation
3rd Jan 20127:00 amRNSRaises $3.5 Million Debt Facility
30th Dec 201110:45 amRNSTotal Voting Rights
19th Dec 20118:31 amRNSPuriCore Receives Two Major Contracts-Replacement
19th Dec 20117:54 amRNSPuriCore Receives Two Major Contracts
14th Dec 20117:00 amRNSAgriculture System Confirmed for Use by EPA
13th Dec 201112:44 pmRNSConvertible loan notes extension
18th Nov 20113:42 pmRNSInterim Management Statement
21st Oct 201111:57 amRNSConvertible Loan Notes Update
10th Oct 20118:21 amRNSHolding(s) in Company
22nd Sep 20114:35 pmRNSBoard and Organisational Changes
16th Sep 201111:19 amRNSNew $1.9million Debt Facility Agreed
5th Sep 20114:40 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.